Christina Addison is a laboratory research scientist at the Ottawa Hospital Research Institute, and an Associate Professor at the University of Ottawa. She works closely with surgeons and oncologists and has a long-standing interest in clinical correlative analyses. The laboratory is also focused on analysis and identification of circulating or tissue-derived predictive biomarkers associated with cancer outcomes. A major current focus in the lab is regarding evaluation of miRNA and its ability to be used to identify patients at higher risk of tumor recurrence or metastasis, or treatment response.
1. Kirby A, Suchy M, Graf D, Calvert, ND, Charlton TA, Ben RN, Addison CL, Shuhendler A. 2024. It’s a trap! Aldolase-prescribed C4-deoxyfluorination affords intracellular trapping and the tracing of fructose metabolism by PET. J Nucl Med. 2024 Mar 1;65(3):475-480. doi: 10.2967/jnumed.123.266905 (impact factor 11.1).
2. Zhao H, Pond G, Simos D, Wang Z, Robertson S, Singh G, Vandermeer L, Clemons M, Addison CL. 2023. Doxycycline-induced changes in circulating MMP or TIMP2 levels are not associated with skeletal-related event- free or overall survival in bone metastatic breast cancer patients. Cancers: Special issue “Invasion and Progression of Solid Tumors in Bone”. 15, 571. doi.org/10.3390/cancers15030571 (impact factor 6.6) Senior Author.
3. *Allen V, Coulombe J, Zhao H, *Kreps LM, Cook DP, Pryce B, Clemons M, Vanderhyden BC, Gray DA, Addison CL. 2022. VIVA1: a more invasive subclone of MDA-MD-134VI invasive carcinoma cells with increased metastatic potential in xenograft models. Br J Cancer. 2022 Jul;127(1):56-68. doi:10.1038/s1416-022-01778-7. Epub 2022 Mar 22. PMID 35318435 (impact factor 8.8) Senior Author.
4. *Gunn SA, *Kreps LM, Zhao H, Landon K, *Ilacqua JS, Addison CL. 2022. Focal adhesion kinase inhibitors prevent osteoblast mineralization in part due to suppression of Akt-mediated stabilization of osterix. J Bone Oncol. 2022 May 13;34”100432. Doi: 10.1016/j.jbo.2022.100432.ecollection 2022 Jun. PMID:35620245 (impact 3.1) Senior Author.
5. Beltran-Bless AA, Murshed M, Zakikhani M, Kuchuk I, Bouganim N, Robertson S, Kekre N, Vandermeer L, Li J, Addison CL, Rauch F, Clemons M, Kremer R. 2021. Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients. Bone Rep. 2021 Oct 22;15:101145. doi: 10.1016/j.bonr.2021.101145. eCollection 2021 Dec. (impact factor 3.7).
6. Brun E, Calvert N, Suchý M, Kirby A, Melkus G, Garipov R, Addison CL, Shuhendler A. 2021. Mapping Vitamin B6 Metabolism by HydrazoCEST Magnetic Resonance Imaging. Chemical Communications (Camb).;Oct 19;57(83):10867-10870. doi: 10.1039/d1cc03704h (impact factor 6.2)
7. *Kreps L, Addison CL. 2021. Targeting intercellular communication in the bone microenvironment to prevent disseminated tumor cell escape from dormancy and bone metastatic tumor growth. Int J of Mol Sci. Mar 13;22(6):2911. doi: 10.3390/ijms22062911. (impact 5.6) Senior Author.
8. Sulaiman A, McGarry S, Chambers J, Al-Kadi E, Phan A, Li L, Mediratta K, Dimitroulakos J, Addison C, Li X, Wang L. 2020. Targeting hypoxia sensitizes TNBC to cisplatin and promotes inhibition of both bulk and cancer stem cells. Int J Mol Sci. Aug 12;21(16):5788. Doi 10.3390/ijms21165788. (impact 5.9)
9. Dufresne J, Bowden P, Thavarajah T, Florentinus-Mefailoski A, Chen ZZ, Tucholska M, Norzin T, Ho MT, Phan M, Mohamed N, Ravandi A, Stanton E, Slutsky AS, Dos Santos CC, Romaschin A, Marshall JC, Addison C, Malone S, Heyland D, Scheltens P, Killestein J, Teunissen C, Diamandis EP, Siu KWM, Marshall JG. 2019. The plasma peptides of breast versus ovarian cancer. Clin Proteomics. Dec 23;16:43. doi: 10.1186/s12014-019-9262-0. eCollection 2019. (impact factor 2.568)
10. Dufresne J, Bowden P, Thavarajah T, Florentinus-Mefailoski A, Chen ZZ, Tucholska M, Norzin T, Ho MT, Phan M, Mohamed N, Ravandi A, Stanton E, Slutsky AS, Dos Santos CC, Romaschin A, Marshall JC, Addison C, Malone S, Heyland D, Scheltens P, Killestein J, Teunissen CE, Diamandis EP, Michael Siu KW, Marshall JG. 2018. The plasma peptides of ovarian cancer. Clin Proteomics. Dec 21;15:41. doi: 10.1186/s12014-018-9215-z. eCollection 2018. (impact factor 2.568)
